Gardasil DTC was the chief factor behind a 21% increase in Merck marketing and administrative expenses for the fourth quarter of 2006, followed by consumer promotion of Zostavax and spending on the Januvia launch, said CEO Dick Clark in a Q4 earnings report.
Gardasil DTC was the chief factor behind a 21% increase in Merck marketing and administrative expenses for the fourth quarter of 2006, followed by consumer promotion of Zostavax and spending on the Januvia launch, said CEO Dick Clark in a Q4 earnings report.
From the March 01, 2007 Issue of MM+M - Medical Marketing and Media
Get the most out of 
Register for free and enjoy unlimited access to:
